Bavarian Nordic partners up with Dynavax on hepatitis B vaccine

The two firms expect to launch the new vaccine in Germany in Q4 2021.

Photo: Bavarian Nordic / PR

Danish pharmaceutical company Bavarian Nordic is entering into a marketing and distribution agreement with Dynavac for the launch of a new hepatitis B vaccine in Germany, according to a press release published on Thursday.

Bavarian Nordic will market and distribute the Heplisav B vaccine for Dynavax. The companies expect it to be launched in the fourth quarter of 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs